Market revenue in 2023 | USD 63.8 million |
Market revenue in 2030 | USD 76.7 million |
Growth rate | 2.7% (CAGR from 2023 to 2030) |
Largest segment | Product registration & clinical trial applications |
Fastest growing segment | Legal representation |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Regulatory consulting, Legal representation, Regulatory writing & publishing, Product registration & clinical trial applications, Regulatory Submissions, Regulatory Operations, Other services |
Key market players worldwide | Genpact Ltd, Criterium Inc., Promedica International, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, Labcorp Drug Development, FREYR Battery Inc, Cencora Inc, Pharmexon, QVigilance, BlueReg Group, ZEINCRO Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regulatory affairs outsourcing market will help companies and investors design strategic landscapes.
Product registration & clinical trial applications was the largest segment with a revenue share of 25.86% in 2023. Horizon Databook has segmented the Singapore regulatory affairs outsourcing market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, regulatory submissions, regulatory operations, other services covering the revenue growth of each sub-segment from 2018 to 2030.
Presence of manufacturing units of several multinational pharmaceutical & biotechnology companies, such as Applied Biosystems, Baxter, CIBA Vision, Becton Dickinson, Medtronic, Fisher Scientific, and Siemens Medical Instruments, is anticipated to contribute toward market growth.
In addition, unlike many other Asian countries, Singapore has strong IP rights protection system, which is anticipated to further increase market attractiveness of the country. Strategic initiatives undertaken by the companies to expand their local presence is also anticipated to have a positive impact on the growth of regulatory services.
For instance, in July 2019, NeoGenomics and PPD announced the opening of NeoGenomics clinical trials testing laboratory for oncology in Singapore.
Horizon Databook provides a detailed overview of country-level data and insights on the Singapore regulatory affairs outsourcing market , including forecasts for subscribers. This country databook contains high-level insights into Singapore regulatory affairs outsourcing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account